Products for Research Use Only

INY-05-040

CAT: 0804-HY-160469-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-160469-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
INY-05-040 is an AKT degrader that can selectively and quickly degrade all three AKT isoforms. INY-05-040 exhibits anti-cancer activity. INY-05-040 can inhibit downstream signaling and cell proliferation in 288 cancer cell lines. INY-05-040 can suppress AKT signaling and induces the stress mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK) . INY-05-040 is effective for breast cancer lines with a low-baseline activation of stress MAPK pathway. INY-05-040 can be studied for anti-cancer research[1][2][3].
CAS Number
2503018-29-7
UNSPSC
12352005
Target
Akt; PROTACs
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/iny-05-040.html
Purity
98.67
Solubility
DMSO : ≥ 100 mg/mL
Smiles
C[C@H]1C2=C(N3CCN(CC3)C([C@@H](C4=CC=C(C=C4)Cl)CNCCCCCCCCCCC(N[C@@H](C(C)(C)C)C(N5[C@@H](C[C@H](C5)O)C(N[C@H](C6=CC=C(C7=C(C)N=CS7)C=C6)C)=O)=O)=O)=O)N=CN=C2[C@@H](C1)O
Molecular Formula
C55H76ClN9O6S
Molecular Weight
1026.77
References & Citations
[1]Erickson E C, et al. Multi-omic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation[J]. bioRxiv, 2022: 2022.10. 11.511726.|[2]Chen, C., et al., (2024) . Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors. Cells, 13 (12), 1061.|[3]Wu, Y., et al., (2025) . Pharmacodynamics of Akt drugs revealed by a kinase-modulated bioluminescent indicator. Nature chemical biology, 21 (8), 1194–1204.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported